Benzinga | May 7, 2021 08:16AM EDT

Morgan Stanley Maintains Overweight on Guardant Health, Lowers Price Target to $160

Morgan Stanley maintains Guardant Health (NASDAQ:GH) with a Overweight and lowers the price target from $175 to $160.